Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

ABSTRACT: Plasmablastic lymphoma (PBL) is a rare and aggressive type of non-Hodgkin lymphoma with biological features that overlap between B-cell lymphoma and plasma cell neoplasm. There is currently no established standard treatment. However, intensive combination regimens, such as EPOCH, are recommended. There is a paucity of data regarding outcomes of hematopoietic cell transplantation (HCT) in this disease. Herein, we analyze data of patients with PBL who received autologous (autoHCT) or allogeneic (alloHCT) transplants using the Center for International Marrow and Transplant Research (CIBMTR) Registry. Between 2015 and 2024, a total of 186 and 31 patients underwent autoHCT and alloHCT, respectively, and met eligibility for the study. In the autoHCT group, 3-year overall survival (OS) was 75.5%

SUBMITTER: Al-Juhaishi T 

PROVIDER: S-EPMC13405239 | biostudies-literature | 2026 Oct

REPOSITORIES: biostudies-literature